Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Femasys Inc. (NASDAQ: FEMY) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As an emerging growth company and smaller reporting company, Femasys files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events affecting its business, capital structure and listing status.
Through these filings, investors can review detailed information about Femasys’ women’s health portfolio, including fertility products such as FemaSeed Intratubal Insemination and FemVue, and the FemBloc permanent birth control system. Current reports on Form 8-K have described milestones like FDA 510(k) clearance for the FemVue Controlled diagnostic device, IDE approval to advance the final phase of the FINALE pivotal trial for FemBloc, and international regulatory approvals for FemBloc in Europe and the UK. Other 8-K filings outline financing transactions, including senior secured convertible notes and associated warrants, as well as underwritten equity offerings.
Femasys’ filings also disclose its Nasdaq Capital Market listing under the symbol FEMY, notices related to continued listing requirements, and responses such as capital raises or bid-price compliance plans. Registration statements on Form S-1 and S-1/A provide further detail on offered securities, use of proceeds, risk factors and forward-looking statements related to the company’s fertility and permanent birth control strategy.
On Stock Titan, these FEMY filings are updated in real time from EDGAR and paired with AI-powered summaries that highlight key points in lengthy documents. Users can quickly locate 10-K and 10-Q reports, 8-K event disclosures, registration statements and other filings, and use AI-generated explanations to understand complex sections on clinical development, regulatory pathways, financing terms and Nasdaq compliance without reading every page.
FEMASYS INC reported that Chief Operating Officer John Charles Canning received a grant of stock options as part of his compensation. The award covers 150,000 options to purchase common stock at an exercise price of $0.38 per share, expiring on March 30, 2036.
The options vest in equal annual installments over four years, beginning on March 30, 2027, and each vesting installment requires that he remain employed by the company or one of its subsidiaries on the applicable vesting date.
Femasys Inc Chief Operating Officer John Charles Canning filed an initial Form 3 showing his beneficial ownership in the company. He reported holding 30,000 shares of Femasys common stock, owned directly. The filing records his position but does not report any recent share purchases or sales.
Femasys Inc. appointed John Canning as Chief Operating Officer, effective March 30, 2026, and entered into an employment agreement outlining his compensation and equity incentives. He brings more than 25 years of medical device leadership experience from Terumo Aortic, Bolton Medical, and Medtronic.
Mr. Canning will receive a $450,000 annual base salary and a target annual bonus equal to 40% of base salary. As a material inducement to join Femasys under Nasdaq Listing Rule 5635(c)(4), he was granted a nonstatutory option to purchase 150,000 shares, vesting over four years, with the exercise price set at the Nasdaq closing price on the March 30, 2026 grant date. If terminated without cause or he resigns for good reason, he is entitled to nine months of salary continuation, unpaid prior-year bonus, and subsidized COBRA premiums, subject to a release of claims.
Femasys Inc. files its annual report describing a women’s health portfolio focused on infertility treatment and permanent birth control, alongside significant financial and regulatory risks. The company highlights FDA‑cleared products such as FemaSeed intratubal insemination, FemVue, FemSperm, FemCerv and FemChec, plus its late‑stage FemBloc non‑surgical permanent birth control system now in a pivotal trial under an FDA investigational device exemption.
Femasys reports substantial doubt about its ability to continue as a going concern and a need for additional capital, while also disclosing Nasdaq listing deficiency notices. Clinical data show FemaSeed and FemBloc met primary endpoints with favorable pregnancy and safety outcomes, and management estimates multi‑billion‑dollar U.S. market opportunities for both infertility and permanent contraception.
Femasys Inc. reported 2025 results showing growing sales but continued losses while advancing its women’s health portfolio. Sales for the year ended December 31, 2025 rose to $2.29 million from $1.63 million, driven by its fertility and non-surgical permanent birth control products.
Net loss was $18.63 million, slightly better than $18.82 million in 2024, with operating expenses of $19.01 million. Cash and cash equivalents increased to $9.27 million, and the company believes this will fund operations into the third quarter of 2026.
Strategically, Femasys is expanding U.S. commercialization of its FemaSeed intratubal insemination product alongside the FemSperm sperm preparation line, while advancing FemBloc non-surgical permanent birth control through enrollment in the FINALE pivotal trial, a key step toward potential U.S. FDA approval, following prior approvals in Europe, the UK and New Zealand.
Femasys Inc. Chief Executive Officer Kathy Lee-Sepsick received a grant of Series D-1 warrants as a derivative award. She acquired 68,244 Series D-1 warrants on March 19, 2026, each initially exercisable into one share of common stock at an exercise price of $0.58 per share. The warrants are exercisable at her option, subject to Nasdaq Capital Market limitations and adjustment provisions, and expire on March 19, 2036. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement among the company, Lee-Sepsick and other parties.
Femasys Inc.’s Chief Financial Officer, Dov Elefant, received a grant of 34,122 Series D-1 Warrants on March 19, 2026. The warrants are exercisable into 34,122 shares of common stock at an initial exercise price of $0.58 per share and expire on March 19, 2036.
The award was issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement. Exercise of these warrants is subject to certain limitations under Nasdaq Capital Market rules, which may restrict when and how fully they can be exercised.
Femasys Inc. director Kenneth D. Eichenbaum received 102,366 Series D-1 warrants as a non-cash award. These derivative securities allow him to acquire 102,366 shares of common stock at an exercise price of $0.58 per share, exercisable from March 19, 2026 until March 19, 2036. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement and are subject to exercise limitations under Nasdaq Capital Market rules.
Femasys Inc. director Charles Larsen received a grant of 34,122 Series D-1 Warrants to acquire common stock. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement dated March 19, 2026. Each warrant has an initial exercise price of $0.58 per share of common stock and is subject to anti-dilution adjustments for events such as stock splits or stock dividends. The holder’s ability to exercise the warrants is limited by Nasdaq Capital Market rules. The warrants are exercisable into 34,122 shares of common stock and expire on March 19, 2036, leaving Larsen holding 34,122 Series D-1 Warrants after this grant.
Femasys Inc. is soliciting stockholder votes at a Special Meeting on April 29, 2026 to consider three proposals: (1) authorize a board‑discretion reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑25 to be set by the board prior to May 1, 2027; (2) approve potential issuances of shares upon conversion of senior secured convertible notes and exercise of multiple warrant series to the extent anti‑dilution or price adjustments reduce effective prices below the Nasdaq Minimum Price; and (3) authorize adjournment to solicit additional proxies if needed.
Only holders of record as of March 27, 2026 may vote. Shares outstanding were 60,390,686 as of that record date and total authorized common shares are 200,000,000. The board recommends a vote FOR all three proposals.